Histidine

1. What conditions has Histidine been studied for?

• Metabolic health / metabolic syndrome features: Associations with improved metabolic syndrome factors and glucose homeostasis markers are described in human-focused reviews; histidine was also identified as inversely associated with liver steatosis in NAFLD cohorts.

• Non-alcoholic fatty liver disease (NAFLD) / hepatic steatosis: Multi-cohort human omics analyses plus mechanistic animal and model-organism studies (mice, rats, flies) evaluated histidine status and supplementation.

• Inflammatory bowel disease / colitis and Crohn’s disease-related inflammation: Mouse colitis models showed benefit linked to gut bacteria-mediated histidine biosynthesis during enteral nutrition; broader reviews list inflammatory bowel diseases as targets needing further study.

• Neurological/brain-related outcomes: Reviews propose study in neurological disorders; a systematic review notes neuroprotection and seizure protection in rats; another review focuses on carnosine (a histidine-containing dipeptide) in neurological/psychiatric disorders.

• Atopic dermatitis: Mentioned as an area where further studies are needed.

• Diabetes: Mentioned as an area for further study; human reviews discuss improved markers of glucose homeostasis with supplementation.

• Uraemic anaemia / chronic kidney disease (CKD)-related low histidine: Reviews note circulating histidine declines in CKD and list uraemic anaemia as a potential target needing further study.

• Chronic obstructive pulmonary disease (COPD): Noted as a condition where circulating histidine declines (observational context).

• Ulcers / peptic ulcer concern: Mentioned mainly in the context of safety (no reported peptic ulcers in the cited review), not as a proven indication.

• Malignancies (especially hepatocellular carcinoma, HCC): Single-cell and experimental work examined “high histidine metabolism” in HCC and effects of elevated histidine on tumor immune microenvironment.

• Exercise / muscle performance: Listed as an area needing further study (often via carnosine-related rationale).

• Organ preservation / myocardial protection in cardiac surgery: Histidine has decades of use as a component of preservation/protection solutions (clinical practice context rather than oral supplementation trials).

• Other non-supplement contexts: Histidine is widely used as a buffer/excipient in monoclonal antibody formulations to reduce aggregation (biopharmaceutical formulation research, not a health condition treatment).

2. Does it work in treating those conditions? Summarize the evidence.

• NAFLD: The strongest “treatment-like” evidence in the studies is preclinical. Plasma histidine was strongly inversely associated with steatosis in human cohorts (observational). In multiple animal/model systems, histidine supplementation improved NAFLD (diet-induced NAFLD mouse and flies, ob/ob mouse, ovariectomized rats) and reduced de novo lipogenesis. Mechanistic work implicated microbiota histidine utilization (e.g., FMT from low-histidine donors and mono-colonization with Enterobacter cloacae increased triglyceride accumulation and reduced histidine content).

• Metabolic syndrome / glucose homeostasis: A human-focused review reports that supplementation around 4.0–4.5 g/day and increased dietary histidine intake are associated with improvements in BMI/adiposity and markers such as HOMA-IR, fasting glucose, and 2-hour postprandial glucose, plus lower proinflammatory cytokines and oxidative stress. However, the review explicitly notes uncertainty about causality and mechanism (weight loss vs. increased carnosine vs. both), and the studies do not provide details on trial design or effect sizes.

• Colitis / Crohn’s-related inflammation: Evidence in the studies is preclinical. Enteral nutrition in mouse models (e.g., DSS-induced colitis and an Il10-related model) showed therapeutic potential, and the mechanism was linked to enrichment of Faecalibaculum rodentium and histidine biosynthesis. This supports a histidine-related pathway but does not establish that oral histidine supplementation alone treats Crohn’s disease in humans.

• Neurological outcomes: A systematic review notes in rats that histidine supplementation provides early-stage neuroprotection and could protect against epileptic seizures. Human evidence in the studies is described as ambiguous: one review suggests histidine intake may improve aspects of cognition/appetite/anxiety/sleep potentially via conversion to histamine, but states the relationship is unclear in humans. Separately, a review suggests carnosine (histidine-containing dipeptide) has promising but mixed/early evidence across brain disorders (cell/animal and some human studies), which is indirect evidence for histidine-related biology rather than histidine supplementation per se.

• Cardiac surgery organ preservation/myocardial protection: One review states that “several decades of experience” confirm effectiveness of histidine as a component of preservation/protection solutions. This supports efficacy in that specific medical-use context, but it is not evidence that dietary supplements improve heart outcomes.

• HCC (cancer): The HCC abstract suggests the opposite of a therapeutic effect: elevated histidine concentrations in experimental settings promoted M2 macrophage polarization, weakened T-cell cytotoxicity, and accelerated tumor proliferation, and “high histidine metabolism” correlated with worse immune infiltration and prognosis. This is not a clinical supplementation trial, but it raises a plausible risk signal in certain tumor contexts.

Overall, the studies support potential benefits for metabolic/NAFLD pathways (with strong mechanistic animal data and human observational associations), while human interventional evidence is described as limited and not definitive. Some contexts (e.g., HCC tumor microenvironment) raise concern rather than benefit.

3. What health benefits does it have?

• Metabolic benefits (human-associated): Supplementation around 4.0–4.5 g/day and higher dietary histidine intake are reported to be associated with lower BMI/adiposity and improved glucose homeostasis markers (HOMA-IR, fasting glucose, 2-hour postprandial glucose), plus reductions in proinflammatory cytokines and oxidative stress. The studies note uncertainty about whether benefits are mediated by weight loss, carnosine, or both.

• Potential NAFLD benefit (preclinical + human association): Plasma histidine was inversely associated with steatosis in human cohorts, and supplementation improved NAFLD phenotypes in multiple animal/model systems and reduced de novo lipogenesis.

• Physiological/biochemical roles supporting broad rationale: Histidine has unique roles in proton buffering, metal ion chelation, and scavenging reactive oxygen/nitrogen species; it contributes to erythropoiesis and the histaminergic system. It is also a precursor for histidine-containing dipeptides (notably carnosine) and derivatives (e.g., ergothioneine) with specialized functions.

• Gut microbiome interactions: In NAFLD-related work, circulating histidine patterns were linked to microbiome features (e.g., inverse association with Proteobacteria and association with bacteria lacking histidine utilization pathways), suggesting histidine availability and microbial catabolism may influence host metabolism.

• Possible neurobehavioral effects (uncertain in humans): Reviews suggest histidine intake may reduce appetite, anxiety, and stress responses and improve sleep, potentially via conversion to histamine, but emphasize ambiguity in human evidence.

4. Does it have any downsides or side effects?

• High-dose adverse effects: A review reports that at >24 g/day, histidine intake has been associated with decreased serum zinc and cognitive impairment. It also notes a lack of data for doses between 4.5 and 24 g/day and that no tolerable upper intake level has been established.

• Zinc depletion as a potential concern/biomarker: The same review proposes a “U-shaped curve” of circulating zinc with supplementation that might serve as a tolerance biomarker, implying zinc status should be monitored in higher-dose use.

• Liver disease caution: One review flags concerns from findings of hepatic enlargement, increased ammonia and glutamine, and decreased branched-chain amino acids in plasma, concluding histidine supplementation may be inappropriate in patients with liver disease.

• Histamine-related theoretical concerns: Although histidine is a histamine precursor, one review states that signs of toxicity, mutagenic activity, allergic reactions, or peptic ulcers have not been reported in the context discussed. Still, the histamine pathway is a plausible mechanism for individual sensitivity (not resolved by the studies).

• Potential cancer-context risk signal (HCC): Experimental work in HCC suggests elevated histidine/histidine metabolism may promote an immunosuppressive tumor microenvironment (M2 macrophages, T-cell exhaustion) and tumor proliferation. This does not prove harm from supplementation in humans, but it is a mechanistic caution for certain malignancy contexts.

• Excess intake effects across species: A systematic review notes that excess histidine can be responsible for eating and memory disorders in humans and can induce growth retardation and metabolic dysfunction in multiple species.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not identify specific human genetic variants that predict benefit or harm from histidine supplementation (e.g., no named polymorphisms in histidine transporters, histidine decarboxylase, or histidine catabolic enzymes).

• Tumor genomics-related signal (not classic pharmacogenomics): In hepatocellular carcinoma, a “high histidine metabolism” state was linked to worse immune infiltration and prognosis, and the gene BUD23 was upregulated in that group and negatively correlated with survival; silencing BUD23 reversed immunosuppression in experimental models. This suggests histidine-metabolism gene-expression programs may modify outcomes in HCC, but it does not establish that inherited genetic variation alters response to histidine supplements.

• Microbiome as a response modifier (non-genetic host variation): Multiple studies indicate that microbial capacity to utilize or synthesize histidine (e.g., presence/absence of the histidine utilization “Hut” system; enrichment of histidine-biosynthesizing bacteria) can change histidine availability and metabolic outcomes (e.g., NAFLD, colitis models). This is not pharmacogenomics, but it is a biologically plausible source of inter-individual variability.

Bottom line: based on these studies alone, there is insufficient evidence to claim histidine is beneficial or harmful for specific inherited genetic variants; the strongest “precision” signals relate to tumor metabolic state (BUD23/high histidine metabolism) and microbiome composition rather than germline genetics.

References

1. Histidine in Health and Disease: Metabolism, Physiological Importance, and Use as a Supplement.
   Milan Holeček (2020) - Nutrients
2. Histidine: A Systematic Review on Metabolism and Physiological Effects in Human and Different Animal Species.
   Joanna Moro, Daniel Tomé, Philippe Schmidely, Tristan-Chalvon Demersay, Dalila Azzout-Marniche (2020) - Nutrients
3. Histidine as a versatile excipient in the protein-based biopharmaceutical formulations.
   Jia-Yi Lv, Rahul G Ingle, Hao Wu, Cuihua Liu, Wei-Jie Fang (2024) - International journal of pharmaceutics
4. Understanding the Stabilizing Effect of Histidine on mAb Aggregation: A Molecular Dynamics Study.
   Suman Saurabh, Cavan Kalonia, Zongyi Li, Peter Hollowell, Thomas Waigh, Peixun Li, John Webster, John M Seddon, Jian R Lu, Fernando Bresme (2022) - Molecular pharmaceutics
5. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity.
   Sergio Quesada-Vázquez, Anna Castells-Nobau, Jèssica Latorre, Núria Oliveras-Cañellas, Irene Puig-Parnau, Noemi Tejera, Yaiza Tobajas, Julio Baudin, Falk Hildebrand, Naiara Beraza, Rémy Burcelin, Laura Martinez-Gili, Julien Chilloux, Marc-Emmanuel Dumas, Massimo Federici, Lesley Hoyles, Antoni Caimari, Josep M Del Bas, Xavier Escoté, José-Manuel Fernández-Real, Jordi Mayneris-Perxachs (2023) - Cell reports. Medicine
6. Specific smart sensing of electron-rich antibiotics or histidine improves the antenna effect, luminescence, and photodynamic sterilization capabilities of lanthanide polyoxometalates.
   Meng-Juan Tang, Zhong-Hong Zhu, Yun-Lan Li, Wen-Wen Qin, Fu-Pei Liang, Hai-Ling Wang, Hua-Hong Zou (2025) - Journal of colloid and interface science
7. Enteral nutrition promotes the remission of colitis by gut bacteria-mediated histidine biosynthesis.
   Wanyi Zeng, Jinjie Wu, Hongyu Xie, Haoyang Xu, Dayi Liang, Qilang He, Xiaoya Yang, Chen Liu, Junli Gong, Qiang Zhang, Zhanhao Luo, Yuan Chen, Zhen He, Ping Lan (2024) - EBioMedicine
8. The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence.
   Martin Schön, Aya Mousa, Michael Berk, Wern L Chia, Jozef Ukropec, Arshad Majid, Barbara Ukropcová, Barbora de Courten (2019) - Nutrients
9. Benefits and Adverse Effects of Histidine Supplementation.
   Anna E Thalacker-Mercer, Mary E Gheller (2020) - The Journal of nutrition
10. A novel EGCG-Histidine complex improves gelling and physicochemical properties of porcine myofibrillar proteins: Insight into underlying mechanisms.
    Xiao Guo, Renzheng Wang, Bofu Han, Wei Shao, Lin Chen, Xianchao Feng (2024) - Food chemistry
11. Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming.
    Pengcheng Liu, Fuxin Huang, Peixu Lin, Jiayao Liu, Pincheng Zhou, Jie Wang, Huanhuan Sun, Fan Xing, Haiqing Ma (2025) - Journal of translational medicine
12. A new green approach to L-histidine and β-alanine analysis in dietary supplements using rapid and simple contactless conductivity detection integrated with high-resolution glass-microchip electrophoresis.
    Iva Pukleš, Csilla Páger, Nikola Sakač, Brunislav Matasović, Elvira Kovač-Andrić, Bojan Šarkanj, Mirela Samardžić, Mateja Budetić, Katarína Molnárová, Dean Marković, Ana Vesinger, Marija Jozanović (2024) - Analytical and bioanalytical chemistry
13. Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease.
    Mayra Vera-Aviles, Eleni Vantana, Emmy Kardinasari, Ngat L Koh, Gladys O Latunde-Dada (2018) - Pharmaceuticals (Basel, Switzerland)
14. Structural insights into TRPV2 modulation by probenecid.
    Julia A Rocereta, Toni Sturhahn, Ruth A Pumroy, Tabea C Fricke, Christine Herzog, Andreas Leffler, Vera Moiseenkova-Bell (2025) - Nature structural & molecular biology
15. Regulation of metabolic health by dietary histidine in mice.
    Victoria Flores, Alexandra B Spicer, Michelle M Sonsalla, Nicole E Richardson, Deyang Yu, Grace E Sheridan, Michaela E Trautman, Reji Babygirija, Eunhae P Cheng, Jennifer M Rojas, Shany E Yang, Matthew H Wakai, Ryan Hubbell, Ildiko Kasza, Jay L Tomasiewicz, Cara L Green, Claudia Dantoin, Caroline M Alexander, Joseph A Baur, Kristen C Malecki, Dudley W Lamming (2023) - The Journal of physiology
16. Detection and treatment of biofilm-induced periodontitis by histidine-doped FeSN nanozyme with ultra-high peroxidase-like activity.
    Bowen Shen, Lei Yang, Hengyue Xu, Yangheng Zhang, Dengming Ming, Liying Zhu, Yuxian Wang, Ling Jiang (2023) - Journal of colloid and interface science
17. Effects of β-Alanine Supplementation on Carnosine Elevation and Physiological Performance.
    Jay R Hoffman, Alyssa Varanoske, Jeffrey R Stout (2018) - Advances in food and nutrition research
18. Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease.
    Estifanos Baye, Barbara Ukropcova, Jozef Ukropec, Alan Hipkiss, Giancarlo Aldini, Barbora de Courten (2016) - Amino acids
19. Anti-cancer actions of carnosine and the restoration of normal cellular homeostasis.
    Mark D Turner, Craig Sale, A Christopher Garner, Alan R Hipkiss (2021) - Biochimica et biophysica acta. Molecular cell research
20. Anti-Cancer Effects of Carnosine-A Dipeptide Molecule.
    Monica D Prakash, Sarah Fraser, Jennifer C Boer, Magdalena Plebanski, Barbora de Courten, Vasso Apostolopoulos (2021) - Molecules (Basel, Switzerland)

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.